{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:43:10Z","timestamp":1790840590708,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-EQPX-03"],"award-info":[{"award-number":["ANR-10-EQPX-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-INBS-09-08"],"award-info":[{"award-number":["ANR-10-INBS-09-08"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-52915-0","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T12:01:48Z","timestamp":1728043308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The genomic and transcriptomic landscape of metastastic urothelial cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1739","authenticated-orcid":false,"given":"Yohann","family":"Loriot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-0950","authenticated-orcid":false,"given":"Maud","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5749-0738","authenticated-orcid":false,"given":"Laurene","family":"Syx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-1173","authenticated-orcid":false,"given":"Remy","family":"Nicolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Dupain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Menssouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Duquesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Lavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Nicotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Ngocamus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-1010","authenticated-orcid":false,"given":"Ludovic","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-4916","authenticated-orcid":false,"given":"Lambros","family":"Tselikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Crehange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1129-4978","authenticated-orcid":false,"given":"Luc","family":"Friboulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Castel-Ajgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4345-3598","authenticated-orcid":false,"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Borcoman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Marret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-6424","authenticated-orcid":false,"given":"Francois","family":"Radvanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-6823","authenticated-orcid":false,"given":"Jean-Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-7410","authenticated-orcid":false,"given":"Nicolas","family":"Servant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-077X","authenticated-orcid":false,"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-8189","authenticated-orcid":false,"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-8357","authenticated-orcid":false,"given":"Fabrice","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-4686","authenticated-orcid":false,"given":"Christophe","family":"Le tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bieche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"52915_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"key":"52915_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483\u20131492 (2017).","journal-title":"Lancet Oncol."},{"key":"52915_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).","journal-title":"Lancet"},{"key":"52915_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 383, 1218\u20131230 (2020).","journal-title":"N. Engl. J. Med."},{"key":"52915_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N. Engl. J. Med. 384, 1125\u20131135 (2021).","journal-title":"N. Engl. J. Med."},{"key":"52915_CR6","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa, S. T. et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J. Clin. Oncol. 39, 2474\u20132485 (2021).","journal-title":"J. Clin. Oncol."},{"key":"52915_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Electronic address: clinicalguidelines@esmo.org. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 244\u2013258 (2022).","journal-title":"Ann. Oncol."},{"key":"52915_CR8","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot, Y. et al. THOR Cohort 1 Investigators. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 389, 1961\u20131971 (2023).","journal-title":"N. Engl. J. Med."},{"key":"52915_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","volume":"23","author":"AO Siefker-Radtke","year":"2022","unstructured":"Siefker-Radtke, A. O. et al. Y; BLC2001 Study Group. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 23, 248\u2013258 (2022).","journal-title":"Lancet Oncol."},{"key":"52915_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"Robertson","year":"2017","unstructured":"Robertson et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"52915_CR11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/ng.3692","volume":"48","author":"BM Faltas","year":"2016","unstructured":"Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet 48, 1490\u20131499 (2016).","journal-title":"Nat. Genet"},{"key":"52915_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst, C. D. et al. Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. Cancer Cell 32, 701\u2013715.e7 (2017).","journal-title":"Cancer Cell"},{"key":"52915_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"52915_CR14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324\u20131334 (2015).","journal-title":"Lancet Oncol."},{"key":"52915_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard, C. et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 7, 586\u2013595 (2017).","journal-title":"Cancer Discov."},{"key":"52915_CR16","first-page":"27","volume":"4","author":"G Recondo","year":"2020","unstructured":"Recondo, G. et al. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. NPJ Precis. Oncol 4, 27 (2020).","journal-title":"Oncol"},{"key":"52915_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19971-8","volume":"11","author":"A Vosoughi","year":"2020","unstructured":"Vosoughi, A. et al. Common germline-somatic variant interactions in advanced urothelial cancer. Nat. Commun. 11, 6195 (2020).","journal-title":"Nat. Commun."},{"key":"52915_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"KL Huang","year":"2018","unstructured":"Huang, K. L. et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell 173, 355\u2013370.e14 (2018).","journal-title":"Cell"},{"key":"52915_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","volume":"72","author":"TJ Moss","year":"2017","unstructured":"Moss, T. J. et al. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur. Urol. 72, 641\u2013649 (2017).","journal-title":"Eur. Urol."},{"key":"52915_CR20","doi-asserted-by":"publisher","first-page":"e128728","DOI":"10.1172\/jci.insight.128728","volume":"5","author":"BR Winters","year":"2019","unstructured":"Winters, B. R. et al. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight 5, e128728 (2019).","journal-title":"JCI Insight"},{"key":"52915_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol. Biol. 1711, 243\u2013259 (2018).","journal-title":"Methods Mol. Biol."},{"key":"52915_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"52915_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"52915_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-0716-0327-7_17","volume":"2120","author":"J Racle","year":"2020","unstructured":"Racle, J. & Gfeller, D. EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data. Methods Mol. Biol. 2120, 233\u2013248 (2020).","journal-title":"Methods Mol. Biol."},{"key":"52915_CR25","first-page":"4351","volume":"15","author":"W Liu","year":"2018","unstructured":"Liu, W. et al. Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer. Oncol. Lett. 15, 4351\u20134357 (2018).","journal-title":"Oncol. Lett."},{"key":"52915_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763877","volume":"12","author":"RC Khanolkar","year":"2022","unstructured":"Khanolkar, R. C. et al. TGF\u03b22 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. Front. Immunol. 12, 763877 (2022).","journal-title":"Front. Immunol."},{"key":"52915_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D., Gao, J. & Phillips, S. M. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 1, 1\u201316 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"52915_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563\u2013575.e11 (2022).","journal-title":"Cell"},{"key":"52915_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.eururo.2022.01.026","volume":"81","author":"JA Nakauma-Gonz\u00e1lez","year":"2022","unstructured":"Nakauma-Gonz\u00e1lez, J. A. et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur. Urol. 81, 331\u2013336 (2022).","journal-title":"Eur. Urol."},{"key":"52915_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08085-z","volume":"21","author":"P Grivas","year":"2021","unstructured":"Grivas, P. et al. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer 21, 593 (2021).","journal-title":"BMC Cancer"},{"key":"52915_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.eururo.2022.10.020","volume":"83","author":"F Erlmeier","year":"2023","unstructured":"Erlmeier, F. et al. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. Eur. Urol. 83, 133\u2013142 (2023).","journal-title":"Eur. Urol."},{"key":"52915_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441\u2013457 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"52915_CR33","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"52915_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/ijc.34715","volume":"154","author":"G Sj\u00f6dahl","year":"2024","unstructured":"Sj\u00f6dahl, G. et al. Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer. Int J. Cancer 154, 180\u2013190 (2024).","journal-title":"Int J. Cancer"},{"key":"52915_CR35","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu, C. E. et al. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin. Cancer Res. 27, 5123\u20135130 (2021).","journal-title":"Clin. Cancer Res."}],"updated-by":[{"DOI":"10.1038\/s41467-024-53775-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52915-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52915-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52915-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:03:04Z","timestamp":1730365384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52915-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52915"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52915-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-024-53775-4","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-024-53775-4","URL":"https:\/\/doi.org\/10.1038\/s41467-024-53775-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L.T.: Roche, Seattle Genetics, Rakuten, Nanobiotix, MSD, BMS, Merck Serono, AstraZeneca, GlaxoSmithKline, Novartis, Celgene, Exscientia, ALX Oncology, Seattle Genetics. M.K.: Roche, AstraZeneca. Pernelle Lavaud: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Astra Zeneca, Sanofi, Astellas; Support for attending meetings and\/or travail from Daichi, Ipsen, Astellas, Sanofi, Jannssen, Pfizer; Advisory board from Daichi. L.L.: Hospitalities, Travel, advice board, research grant last 5 years with: Abbott; Adept Field Solutions; Amgen; AstraZeneca; Beckman Coulter; Bayer Boeringer; BMS; Icomed; Illumina, Genomic Health; Guardant health; Lilly; Medimmune; Myriad; Novartis; Pfizer; QualWorld1; Roche; Siemens Healthineer; Taiho Oncology, Thermofisher Sc; VelaDx. E.R.: Travel, advice board, research grant: AstraZeneca, Roche, BMS, GSK, and Clovis. L.F.: Research funding from Debiopharm, Incyte, Relay Therapeutics and Nuvalent and Non financial support from Illumina Inc and Guardant Health. F.F.: no disclosures. Benjamin Besse: grants from 4D Pharma, AbbVie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, Celgene, Cergentis, Chugai Pharmaceutical, Da Voltera, Daiichi Sankyo, Eli Lilly, Ellipse Pharma, Eisai, F-Star, Genmab, Genzyme Corporation, GSK, Hedera Dx, Inivata, Ipsen, Janssen, MSD, Onxeo, OSE Immunotherapeutics, Pfizer, Pharmamar, Roche\/Genentech, Sanofi, Socar Research, Taiho Oncology, Takeda, Tolero Pharmaceuticals, and Turning Point Therapeutics during the conduct of the study. C.M.: Consultant\/Advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion. Principal\/sub-Investigator of Clinical Trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, Xencor. F.A.: grants from Roche, Lilly, Novartis, Pfizer, Daiichi Sankyo, and AstraZeneca outside the submitted work. Y.L.: personal fees, and non-financial support from Sanofi, Janssen, Astellas, Seattle Genetics, Gilead, AstraZeneca, BMS, MSD, Pfizer, Merck KGaA, Pfizer, and Tahio; grants, grants from Celsius, Sanofi, Roche, MSD. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8603"}}